Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Pharmaceuticals2.77%-1.46 ppHealth Care Equipment1.24%-1.46 ppBiotechnology1.31%-0.76 ppManaged Health Care0.64%-0.64 ppLife Sciences Tools & Services0.59%-0.41 ppHealth Care Services0.32%-0.23 ppHealth Care Distributors0.29%-0.16 ppHealth Care Facilities0.13%-0.08 ppHealth Care Supplies0.06%-0.04 ppHealth Care Technology0.02%-0.01 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
1.31%
Industry change · 12M
-0.76 pp
Biotechnology · contribution
-0.762 pp
Company participation
0%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Apr 2026 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| AbbVie → ABBV | United States | $373.6bn | 0.507% | -0.247 pp | -0.320 pp | +11.8% | No |
| Vertex Pharmaceuticals → VRTX | United States | $108.6bn | 0.147% | -0.081 pp | -0.167 pp | -16.1% | No |
| Amgen → AMGN | United States | $186.7bn | 0.253% | -0.099 pp | -0.122 pp | +22.8% | No |
| Gilead Sciences → GILD | United States | $162.4bn | 0.220% | -0.117 pp | -0.098 pp | +26.1% | No |
| Regeneron Pharmaceuticals → REGN | United States | $66.4bn | 0.090% | -0.043 pp | -0.045 pp | +18.7% | No |
| Biogen → BIIB | United States | $27.9bn | 0.038% | -0.013 pp | -0.005 pp | +56.3% | No |
| Incyte → INCY | United States | $19.0bn | 0.026% | -0.012 pp | -0.003 pp | +52.0% | No |
| Moderna → MRNA | United States | $18.1bn | 0.025% | -0.008 pp | -0.002 pp | +61.0% | No |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.